Navigation Links
New Study Shows Cloning from Dried Cells Now Possible
Date:9/8/2008

New Freeze Drying Technology Could Have Widespread Use in Improving Medical

Care and Saving Endangered Animals from Extinction

MT. LAUREL, N.J., Sept. 8 /PRNewswire/ -- Core Dynamics Inc. today announced that cloning with freeze-dried cells is possible for the first time, according to new study findings in the August issue of the research journal PLos One. The company's patented IMT freeze-drying technology was used in the study.

Cloning starts when an egg without genetic material is injected with cells with it. Until now, these cells had to be fresh or frozen and thawed just before injection.

In the investigation, the cells were freeze-dried and stored for three years at room temperature. They then were revived by adding water and successfully used to form sheep embryos.

The key benefit is that now clinicians can preserve cells with minimal storage costs for long periods of time. "We didn't see any reduction in the viability of the cells during the three years; therefore, theoretically they could be stored indefinitely under optimal conditions," explained lead investigator Professor Pasqualino Loi, DVM, PhD, department of Comparative Biomedical Sciences, Teramo University, Teramo, Italy.

"This milestone could signal the dawn of a new era in biomedicine by facilitating the use of cells that can regenerate damaged tissue in the cartilage and heart and other tissue or organs, as well as by significantly increasing access to red-blood, bone-marrow and other cells currently used in medical care," Dr. Loi added.

Scientists have long been trying to freeze dry cells to allow for easier handling, reduced storage costs and better availability. Storing frozen cells with liquid nitrogen is the current gold standard but is costly and complicated, with special transportation and storage requirements. It also can cause cell damage and contamination, and the needed equipment is not always available in developing countries.

Dr. Loi also noted that the new technology also could assist with conserving animals threatened with extinction by allowing for easy and inexpensive transportation and storage of cells of endangered species. "This could be invaluable, given we have no way of recovering these species once they're gone."

"These results validate the potential of our freeze-drying technology across a broad range of scientific, medical and commercial applications," said Dr. Amir Arav, DVM, PhD, Core Dynamics' founder and chief technology officer. "We look forward to working with the medical community to advance products for clinical use."

About Core Dynamics:

Core Dynamics is a privately held biotechnology company that is stretching the horizons of the science of cryopreservation. The company is active in the research and development of unique freezing, thawing and freeze drying technologies that are being applied in work with cell preservation, blood transfusion, and tissue and organ transplantation. The company has developed unique protocols, equipment and solutions for cryopreservation of cells and of tissues such as osteo-articular cartilage and of whole organs. Core Dynamics' Research and Development center is located in Ness Ziona, Israel, with a staff of over 30 research scientists and support personnel. Company management has wide experience in the fields of medicine, cryopreservation and cell biology. The company's commercial offices are located in Mt. Laurel, New Jersey. Core Dynamics hopes to develop additional applications through research partnerships involving its advanced cryopreservation technologies. For more information, visit http://www.coredynamics.com.

Media Contact:

Rachel Kessler

Lazar Partners

Cell: 917-660-0608

Office: 212-599-1265

E-mail: rkessler@lazarpartners.com


'/>"/>
SOURCE Core Dynamics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
2. New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence
3. Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium
4. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
5. Study Suggests a Possible Way to Offset Chemobrain Memory Loss
6. Cytopia Commences Second Phase II Study in Brain Cancer
7. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
8. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
9. CDC Misses Target With Flawed MMR/Autism Study
10. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
11. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...
(Date:8/7/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... 30, 2017.  All comparisons, unless otherwise noted, are to the ... Second Quarter 2017 Highlights include: ... increase of 3.5% Total prescriptions dispensed of ... 7.5% versus 7.6% Gross profit per ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... A recent report indicates ... biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines their expectations ... ruling. , Presented as part of the Beckman Coulter Life Sciences Virtual ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... The next ... now being accepted. , Students who successfully complete the seven-week long Patient Care ... Nurse Assistant (CNA). The average starting salary for a CNA in Kalamazoo is $24,428.* ...
(Date:8/16/2017)... ... 2017 , ... Greenfield Advisors is honored to be named to Inc. Magazine’s ... in a row. The Inc. 5000 list honors private businesses across the country that ... list once is a great accomplishment, but for us to be included again goes ...
(Date:8/16/2017)... ... August 16, 2017 , ... Any Lab Test ... The company ranked #4429 on the newly released, 36th annual Inc. 5000 , ... unique look at the most successful companies within the American economy’s most dynamic segment ...
(Date:8/16/2017)... New York (PRWEB) , ... August 16, 2017 , ... ... could minimize its appearance with diet and exercise. In fact, cellulite can't always be ... a safer and more effective treatment available to select physicians nationwide. Dr. Kenneth Rothaus ...
Breaking Medicine News(10 mins):